STERLING TILUDRONATE SHOWS EQUAL EFFICACY TO ETIDRONATE FOR PAGET's
Executive Summary
STERLING TILUDRONATE SHOWS EQUAL EFFICACY TO ETIDRONATE FOR PAGET's disease in clinical trials, Jean-Yves Reginster, MD/PhD, Georgetown, told a workshop on bisphosphonates during the National Osteoporosis Foundation's Third International Symposium held in Washington, D.C. March 5. Three and six month treatment with tiludronate was "at least as, if not more, [efficacious] than etidronate," Reginster stated. Sterling Winthrop anticipates filing an NDA this year for tiludronate as a treatment for Paget's disease.